NCT03801642View on ClinicalTrials.gov

Dapagliflozin In Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 29, 2019

Primary Completion Date

July 7, 2022

Study Completion Date

July 7, 2022

Conditions
Alzheimer Disease
Interventions
DRUG

Dapagliflozin

10 mg oral tablets taken once daily for 12 weeks

OTHER

Placebo

Placebo tablet (matched in size and color to active tablet) taken once daily for 12 weeks

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
lead

Jeff Burns, MD

OTHER

NCT03801642 - Dapagliflozin In Alzheimer's Disease | Biotech Hunter | Biotech Hunter